, a specialty pharmaceutical business focused on the advancement and commercialization of innovative therapies for the treatment of acute and breakthrough discomfort, today announced the pricing of its initial open public giving of 8 million shares of common share at $5.00 per share. All the common stock will be offered by AcelRx. The shares are anticipated to begin trading on the Nasdaq Global Market under the ticker symbol ACRX on February 11, 2011. Piper Jaffray & Co. Is normally acting as single book-running Cowen and manager and Company, LLC, Canaccord Genuity Inc., and JMP Securities LLC are performing mainly because co-managers for the giving. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 10, 2011. The offering is being made by means of a prospectus forming area of the effective sign up statement, copies which may be obtained, when obtainable, by contacting Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by calling 1-800-747-3924..Juliana McElrath, M.D., Ph.D., Lawrence Corey, M.D., and Peter B. Gilbert, Ph.D. For the HVTN 505 Study Team: Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine The epidemic infection caused by the human immunodeficiency virus type 1 is currently in its fourth decade, with an estimated 2.5 million new infections happening annually worldwide. 1 The number of newly infected persons, although diminishing, outpaces the real number of patients who have initiate antiretroviral therapy. Despite a true number of successful prevention interventions that have been reported, including preexposure prophylaxis and treatment as prevention,2-9 supreme control of the HIV epidemic will most likely come just with the advancement of a effective and safe preventive vaccine.